IL1B and amyotrophic lateral sclerosis: It is also important to underline that clinical studies using the Interleukin-1 receptor antagonist Anakinra have not demonstrated a reduction in the neuroinflammation in ALS, suggesting that NLRP3 inflammasome might not play a major role in ALS or that this disease is mainly driven by IL-18 and not IL-1β [87].